Lung Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lung Therapeutics, Inc.
The series A fundraising will help Locana bring CRISPR gene editing to diseases with dysfunctional RNA. Artizan and OncoMyx are among the other firms with recent series A rounds.
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.
June venture capital financings for emerging companies totaled more than $688.8m, ranging from an undisclosed round for Avitide to a $120m Series B for Rubius Therapeutics.
Athenex and Immuron launched IPOs in the US, but June has otherwise been a pretty quiet month for new biopharma financings – so far. The largest VC round so far this month is Checkmate's $27m Series B and the biggest public offering was conducted by CTI BioPharma, raising $45m.